Table 1.
Pharmacokinetic parameter estimations of DTX in plasma of normal balb/c mice after being treated with 2DTX2 (4 mg/kg, IV) through a tail vein and 2DTX2 (4 mg/kg, SC), 2DTX2/CIS2 (4 mg/kg each, SC), P13L0.15O1.52D2C2 (4 mg/kg each, SC), 2DTX1/CIS1 (2 mg/kg each, SC), and P13L0.15O1.52D1C1 (2 mg/kg each, SC).
| Parameters | 2DTX2 (IV) | 2DTX2 (SC) | 2DTX2/CIS2 | P13L0.15O1.52D2C2 | 2DTX1/CIS1 | P13L0.15O1.52D1C1 |
|---|---|---|---|---|---|---|
| AUC0–72 (ng/h/mL) | 1387.92 (125.25) | 584.56 (34.51) | 1231.37 (242.24) | 1110.42 (181.46) | 816.68 (123.29) | 641.65 (67.66) |
| AUC0–inf (ng/h/mL) | 1454.96 (116.97) | 820.32 (158.14) | 1353.92 (366.51) | 1489.74 (724.61) | 1094.81 (512.935) | 787.47 (85.82) |
| Cmax (ng/mL) | 418.33 (46.53) | 52.76 (10.98) | 412.23 (66.50) | 108.06 (18.43) | 197.74 (71.78) | 54.19 (6.56) |
| Tmax (h) | 0.63 (0.25) | 0.88 (0.75) | 0.5 (0) | 0.88 (0.75) | 0.75 (0.29) | 2.0 (0.00) |
| T1/2 (h) | 11.86 (1.27) | 28.56 (4.83) | 14.45 (2.48) | 19.57 (10.38) | 18.97 (6.60) | 22.52 (3.16) |
| CL (mL/h/kg) | 2762.58 (221.83) | 4998.16 (848.12) | 3089.60 (667.77) | 3102.56 (1180.29) | 2079.57 (739.80) | 2560.50 (253.71) |
| V (mL/kg) | 47,222.73 (5646.61) | 201,497.3 (4984.60) | 64,173.62 (18,284.55) | 75,234.89 (5935.48) | 52,925.09 (15,376.22) | 82,359.13 (3530.80) |
| MRT (h) | 8.50 (1.69) | 23.92 (1.80) | 10.87 (1.94) | 16.36 (6.78) | 18.48 (9.12) | 19.37 (3.48) |
Data are presented as the mean (SD) (n = 3 or 4).
AUC0-72: area under the receiver operating curve at 0–72 h; AUC0–inf: area under the receiver operating curve at 0 to infinity; Cmax: maximum plasma drug concentration; Tmax: the time to reach Cmax; T1/2: half-life of the drug; CL: clearance; V: volume of the distribution; MRT: mean residence time; IV: intravenous; SC: subcutaneous.